Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DC AML primed T-cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on DC AML primed T-cells (Feb 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DC AML primed T-cells | DC/AML primed T cells | Limited information is currently available on DC AML primed T-cells (Feb 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07374029 | Phase I | DC AML primed T-cells Decitabine + Venetoclax DC AML Vaccine + Sargramostim | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | Not yet recruiting | USA | 0 |